Median follow-up was 3.0 years . Overall, 95.1 percent of sufferers in the sitagliptin group and 94.1 percent of these in the placebo group completed the study, with 26.1 percent and 27.5 percent of all study patients, respectively, discontinuing research medication prematurely. Vital position was obtained for 97.5 percent of patients . The features of the individuals at baseline were well balanced between the study groups regarding demographic features and the use of antihyperglycemic agents and secondary cardiovascular prevention medications .5 percent, and patients had been coping with diabetes for a mean of 11.1 years. Glycemic Control At 4 a few months, the mean glycated hemoglobin ideals were 0.4 %age points lower in the sitagliptin group than in the placebo group.27) . Patients in the sitagliptin group received fewer additional antihyperglycemic agents than did those in the placebo group during the study period and were less inclined to begin long-term insulin therapy .As yet, studies have not really analyzed the influence of capsule endoscopy on clinical decision-making and therapeutic outcomes in IBD. According to research presented by scientists from Mount Sinai INFIRMARY, use of the video capsule significantly improves clinical outcomes. For the study, the united team of researchers reviewed the results of capsule endoscopy in patients with IBD-related indications. Overall, for 20 of the 21 patients in whom major diagnostic results were uncovered using capsule endoscopy, therapeutic decisions predicated on the results led to clinical improvement in patient outcome. In groups A and B, an lack of small bowel findings in 30 of 32 patients helped eliminate CD. Throughout the average follow-up of 19 months, no evidence of CD developed, leading to a negative predictive value for the capsule study of completely in this setting.